SRR1313157
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.530
- MTORC1_SIGNALING+0.500
- GLYCOLYSIS+0.420
- CHOLESTEROL_HOMEOSTASIS+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- MYC_TARGETS_V2+0.370
- HYPOXIA+0.350
- G2M_CHECKPOINT+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.130
- HEDGEHOG_SIGNALING-0.100
- PEROXISOME-0.050
- TGF_BETA_SIGNALING-0.050
- MYOGENESIS-0.040
- BILE_ACID_METABOLISM-0.010
- APOPTOSIS+0.040
- INTERFERON_GAMMA_RESPONSE+0.040
- MITOTIC_SPINDLE+0.040
- ANGIOGENESIS+0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-60-2723-01A-01R-0851-07 | — | cohortSQ2 | 0.902 |
| 2 | SRR11296801 | — | — | 0.889 |
| 3 | BS_SHJA4MR0 | high-grade glioma | — | 0.875 |
| 4 | MDT-AP-0428 | Med | Medulloblastoma | 0.865 |
| 5 | TCGA-51-4079-01A-01R-1100-07 | — | cohortSQ2 | 0.864 |
| 6 | MDT-AP-0368 | Med | Medulloblastoma | 0.853 |
| 7 | s0094253 | — | — | 0.849 |
| 8 | MDT-AP-1381 | Med | Medulloblastoma | 0.846 |
| 9 | C3N-00574 | — | cohortA4 | 0.843 |
| 10 | BS_V4W81SFC | Supratentorial Ependymoma | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.500 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.420 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |